Company intelligence / Profile preview

Idris Oncology

Ownership: Private
Development stage: Preclinical

Overview

Idris Oncology has developed a novel "flow biopsy" device that captures circulating tumor cells and DNA directly from the bloodstream using a specialized coated wire. This approach enables more sensitive detection of cancer biomarkers compared to traditional tissue or liquid biopsies. The company has demonstrated proof-of-concept in animal models for both safety and efficacy, paving the way toward first-in-human clinical trials. No published human clinical results yet.

Therapeutic areas: Oncology
Modalities: Device
Industry: Molecular Diagnostics

Partnerships

Ongoing Eurostars TM project collaboration; open to further collaborations with academic groups or industry partners.No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Idris Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Idris Oncology.

Explore the full profile